|
an open-label, multi-center, single arm, rollover study of gme751 (proposed pembrolizumab biosimilar) in
participants who are eligible for continued pembrolizumab treatment after participation in cgme751a12101 or
cgme751a12301 studies
|
20-11-202419-05-2028
|
Penyelidik Bersama
|
|
a phase iii, open-label, sponsor-blind, randomized study of dato-dxd with or without osimertinib versus platinum-based doublet chemotherapy for participants with egfr-mutated locally advanced or metastatic non-small cell lung cancer whose disease has...
|
26-09-202425-03-2028
|
Penyelidik Bersama
|
|
development of novel exosomal microrna signature as prognostic biomarkers for breast cancer treatment.
|
12-09-202411-09-2027
|
Penyelidik Bersama
|
|
a phase 1b/2, open-label, randomized study of vudalimab in combination with chemotherapy or pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer
|
13-05-202412-08-2027
|
Penyelidik Bersama
|
|
elucidating the role of lrg1 in folfox chemosensitization and metabolic secretome modification in colorectal cancer via metabolomic and metallomic approaches
|
01-08-202431-07-2027
|
Penyelidik Bersama
|
|
a randomized, double-blind, parallel-group study to compare efficacy, safety, and immunogenicity of gme751 (proposed pembrolizumab biosimilar) and eu-authorized keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung can
|
21-12-202320-06-2027
|
Penyelidik Bersama
|
|
the correlation of pd-l1 positivity with dna mismatch repair and their associations with tumour-infiltrating lymphocytes in triple negative breast cancer patients
|
01-11-202431-10-2026
|
Penyelidik Bersama
|
|
tumour budding in invasive laryngeal squamous cell carcinoma and its correlation with clinicopathological parameters and overall survival in hospital canselor tuanku muhriz (hctm).
|
27-06-202426-07-2026
|
Penyelidik Bersama
|
|
a phase 3 study to evaluate zimberelimab (ab122) monotherapy compared to standard chemotherapy or zimberelimab combined with ab154 in front-line, pd-l1-positive locally advanced or metastatic non-small cell lung cancer
|
25-03-202124-12-2025
|
Penyelidik Bersama
|
|
exploring nuclear security culture: a questionnaire-based survey
|
16-05-202415-11-2025
|
Ketua Projek
|
|
phase 1 study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the anti‑ox40 agonist monoclonal antibody bgb-a445 in combination with the anti-pd-1 monoclonal antibody tislelizumab in patients with advanced s
|
10-11-202209-11-2025
|
Penyelidik Bersama
|
|
a randomized, double-blind study evaluating the efficacy, safety, and immunogenicity of abp 206 compared with opdivo® (nivolumab) in subjects with treatment-naïve unresectable or metastatic melanoma
|
04-01-202403-10-2025
|
Penyelidik Bersama
|
|
a randomized, double-blind study evaluating pharmacokinetic similarity of abp 206 compared with opdivo® (nivolumab) in resected stage iii or stage iv melanoma subjects in the adjuvant setting
|
22-06-202321-08-2025
|
Penyelidik Bersama
|
|
a randomized, double-blind, parallel group, equivalence, multicenter phase iii trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of hd204 to avastin® in patients with metastatic or recurrent non-squamous non-small cell lung.
|
08-08-201930-03-2025
|
Penyelidik Bersama
|
|
stella – a randomized, multicenter, multinational, double-blind study to assess the efficacy and safety of mb02 (bevacizumab biosimilar drug) versus avastin® in combination with carboplatin and paclitaxel for the treatment of subjects with stage iiib/iv n
|
08-02-201807-03-2021
|
Penyelidik Bersama
|